New hope for PCV patients: higher-dose eye injection tested in china

NCT ID NCT07365371

First seen Jan 27, 2026 · Last updated May 06, 2026 · Updated 15 times

Summary

This study tests a higher dose (8 mg) of the drug aflibercept in Chinese patients with polypoidal choroidal vasculopathy (PCV), a condition that causes vision loss. About 174 people will receive three initial monthly eye injections, then be split into two groups: one gets additional injections only if the disease is active, the other follows a schedule with a maximum gap of 20 weeks. The goal is to see which regimen better improves vision and controls the disease over 52 weeks.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for POLYPOIDAL CHOROIDAL VASCULOPATHY (PCV) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Affiliated Eye Hospital of Nanchang University

    Nanchang, Jiangxi, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Affiliated Hospital Of Shandong Second Medical University

    Weifang, Shandong, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Beijing Hospital

    Beijing, Beijing Municipality, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Beijing Tongren Hospital, CMU

    Beijing, Beijing Municipality, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Eye & ENT Hospital of Fudan University

    Shanghai, Shanghai Municipality, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Jiangsu Province Hospital , The First Affiliated Hospital with Nanjing Medical University

    Nanjing, Jiangsu, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Jiaxing Hospital of T.C.M

    Jiaxing, Zhejiang, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Renmin Hospital Of Wuhan University

    Wuhan, Hubei, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Shandong Provincial Hospital

    Jinan, Shandong, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

    Shanghai, China

  • Shanxi Eye Hospital

    Taiyuan, Shanxi, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • The First Affiliated Hospital Of Harbin Medical University

    Harbin, Heilongjiang, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • The First Affiliated Hospital of Kunming Medical University

    Kunming, Yunan, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • The First Affiliated Hospital of Zhengzhou University

    Zhengzhou, Henan, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • The First People's Hospital Of Xianyang

    Xianyang, Shaanxi, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • The Second Affiliated Hospital of Zhejiang University School of Medicine

    Hangzhou, Zhejiang, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • The Second Norman Bethune Hospital Of Jilin University

    Jilin, Jilin, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • The Second People's Hospital Of Foshan

    Foshan, Guangdong, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Tianjin Eye Hospital

    Tianjin, Tianjin Municipality, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Xi' AN No.1 Hospital

    Xi'an, Shaanxi, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.